Alnylam Pharmaceuticals, Inc. $ALNY Shares Purchased by Investment Management Corp of Ontario

by · The Markets Daily

Investment Management Corp of Ontario boosted its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 35.4% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 31,521 shares of the biopharmaceutical company’s stock after acquiring an additional 8,244 shares during the quarter. Investment Management Corp of Ontario’s holdings in Alnylam Pharmaceuticals were worth $10,279,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of ALNY. Teacher Retirement System of Texas lifted its position in shares of Alnylam Pharmaceuticals by 3.2% during the 2nd quarter. Teacher Retirement System of Texas now owns 36,408 shares of the biopharmaceutical company’s stock worth $11,872,000 after buying an additional 1,123 shares during the last quarter. Envestnet Asset Management Inc. grew its stake in shares of Alnylam Pharmaceuticals by 33.0% in the 2nd quarter. Envestnet Asset Management Inc. now owns 95,796 shares of the biopharmaceutical company’s stock valued at $31,238,000 after purchasing an additional 23,749 shares during the last quarter. Simon Quick Advisors LLC purchased a new position in Alnylam Pharmaceuticals in the 2nd quarter valued at $222,000. Strs Ohio acquired a new position in shares of Alnylam Pharmaceuticals during the first quarter worth about $7,781,000. Finally, Arrowstreet Capital Limited Partnership increased its position in Alnylam Pharmaceuticals by 4,085.0% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 169,700 shares of the biopharmaceutical company’s stock worth $55,337,000 after purchasing an additional 165,645 shares during the period. 92.97% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently commented on ALNY. Wall Street Zen upgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Monday, November 10th. Royal Bank Of Canada raised their price objective on Alnylam Pharmaceuticals from $435.00 to $500.00 and gave the company an “outperform” rating in a research note on Friday, September 19th. JPMorgan Chase & Co. decreased their target price on Alnylam Pharmaceuticals from $475.00 to $473.00 and set an “overweight” rating on the stock in a research report on Monday, October 13th. Citigroup upped their target price on Alnylam Pharmaceuticals from $527.00 to $583.00 and gave the company a “buy” rating in a report on Tuesday, September 2nd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alnylam Pharmaceuticals in a research note on Wednesday, October 8th. Twenty-three research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $482.17.

Read Our Latest Research Report on Alnylam Pharmaceuticals

Insider Buying and Selling

In other news, EVP Kevin Joseph Fitzgerald sold 12,128 shares of the stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $452.18, for a total transaction of $5,484,039.04. Following the transaction, the executive vice president directly owned 21,264 shares in the company, valued at $9,615,155.52. This represents a 36.32% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Jeffrey V. Poulton sold 3,821 shares of Alnylam Pharmaceuticals stock in a transaction on Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total transaction of $1,727,283.05. Following the completion of the transaction, the executive vice president owned 54,052 shares in the company, valued at approximately $24,434,206.60. This trade represents a 6.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 60,328 shares of company stock worth $27,288,993 in the last three months. 1.20% of the stock is currently owned by insiders.

Alnylam Pharmaceuticals Trading Down 6.1%

Alnylam Pharmaceuticals stock opened at $430.02 on Tuesday. The stock has a 50-day moving average price of $456.43 and a 200 day moving average price of $404.78. The company has a current ratio of 2.54, a quick ratio of 2.49 and a debt-to-equity ratio of 4.45. The stock has a market cap of $56.81 billion, a PE ratio of 1,791.75 and a beta of 0.30. Alnylam Pharmaceuticals, Inc. has a 52 week low of $205.87 and a 52 week high of $495.55.

Alnylam Pharmaceuticals Profile

(Free Report)

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

Featured Articles